Get the Stockscreener App
8.035
0.19%
-0.015
Biocryst Pharmaceuticals Inc stock is traded at $8.035, with a volume of 1.69M.
It is down -0.19% in the last 24 hours and down -1.53% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$8.05
Open:
$8.105
24h Volume:
1.69M
Relative Volume:
0.37
Market Cap:
$2.05B
Revenue:
$885.72M
Net Income/Loss:
$-457.98M
P/E Ratio:
-4.5229
EPS:
-1.7765
Net Cash Flow:
$293.05M
1W Performance:
-3.08%
1M Performance:
-1.53%
6M Performance:
-14.88%
1Y Performance:
+17.99%
1-Day Range:
$8.02
$8.24
1-Week Range:
$7.97
$8.595
52-Week Range:
$6.00
$11.22
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.035 | 2.05B | 885.72M | -457.98M | 293.05M | -1.7765 |
TAK
Takeda Pharmaceutical Co Adr
|
19.64 | 62.75B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.26 | 48.12B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.965 | 43.82B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
78.72 | 32.53B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.81 | 23.54B | 3.17B | 1.29B | 1.01B | 27.09 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-13-26 | Resumed | JP Morgan | Neutral |
| Feb-18-26 | Resumed | Evercore ISI | Outperform |
| Oct-15-25 | Resumed | TD Cowen | Buy |
| Oct-01-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-25 | Initiated | Wedbush | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
BioCryst Pharmaceuticals, Inc. (BCRX) Options ChainYahoo Finance - Yahoo! Finance Canada
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
People on the Move: BioCryst Forms Scientific Advisory Board of Seven Rare Disease Leaders - BioBuzz
BioCryst Pharmaceuticals stock fell 1.85 percent on October 6 - AD HOC NEWS
BioCryst Pharmaceuticals stock gets USD 20.50 target as BioCryst forms board - AD HOC NEWS
BioCryst Pharmaceuticals stock gets USD 20.50 target as BioCryst forms board - AD HOC NEWS
BioCryst Pharmaceuticals Inc (BO1.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
BioCryst Pharmaceuticals stock gets a new science board - AD HOC NEWS
Discipline and Rules-Based Execution in BCRX Response - Stock Traders Daily
Biocryst Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board - www.marketscreener.com
BioCryst forms scientific advisory board for R&D strategy By Investing.com - Investing.com India
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth - GlobeNewswire
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth - GlobeNewswire
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth - GlobeNewswire
JPMorgan raises target for BioCryst Pharmaceuticals stock - AD HOC NEWS
BioCryst Pharmaceuticals Price Target Raised to $13.00/Share From $12.00 by JP Morgan - Moomoo
BCRX Maintained by JP Morgan -- Price Target Raised to $13.00 - GuruFocus
J.P. Morgan Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Raises Target Price to $13 - Moomoo
Claude AI Just Bought These 2 Pharma Stocks - finance.yahoo.com
(BCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BioCryst Pharmaceuticals, Inc. (BCRX) Options ChainYahoo Finance - Yahoo! Finance Canada
Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks? - finance.yahoo.com
BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation - Stocktwits
BioCryst Pharmaceuticals stock gains 0.92 percent as earnings beat estimates - AD HOC NEWS
Biopharma Stock With Layers of Technical Support in Place - Yahoo Finance
Biopharma Stock With Layers of Technical Support in Place - Schaeffer's Investment Research
BioCryst Eyes $1B Rare-Disease Future Through External Innovation - Yahoo Finance
BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs - AlphaStreet
BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story - Yahoo Finance
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity (NASDAQ:BCRX) - Seeking Alpha
BCRX Downgraded by RBC Capital -- Price Target Lowered to $11.00 - GuruFocus
RBC Downgrades BioCryst to Sector Perform Amid Competitive Pressures - Intellectia AI
BCRX Looks 24.9% Undervalued on GF Value™ Despite Unprofitabilit - GuruFocus
BioCryst Pharma (BCRX): ORLADEYO Growth And Pipeline Catalysts Shape The Long-Term Outlook - RTTNews
BioCryst's Orladeyo Approved for HAE Attack Prevention - Intellectia AI
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease - Yahoo Finance
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease - Stocktwits
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio - manilatimes.net
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio - Yahoo Finance
BCRX Reiterated by Needham -- Price Target Maintained at $16 - GuruFocus
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook - Investing.com Canada
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook - Investing.com India
(BCRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
C5 inhibitors disclosed in Biocryst patents - BioWorld News
BioCryst to Present at Upcoming Investor Conference - marketscreener.com
BioCryst to Present at Upcoming Investor Conference - GlobeNewswire
BioCryst to Present at Upcoming Investor Conference - Yahoo Finance
Morgan Stanley's healthcare conference is set to feature BioCryst on Sept. 15. - Stock Titan
BioCryst stock holds firm after a Q2 revenue beat - ad-hoc-news.de
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biocryst Pharmaceuticals Inc Stock (BCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Amy McKee | Director |
May 18 '26 |
Proposed Sale |
8.94 |
11,180 |
99,906 |
0 |
| Barnes Alane P | Chief Legal Officer |
May 13 '26 |
Sale |
9.54 |
62,500 |
596,250 |
400,703 |
| Barnes Alane P | Chief Legal Officer |
May 13 '26 |
Option Exercise |
5.04 |
62,500 |
315,000 |
463,203 |
| Barnes Alane P | Officer |
May 13 '26 |
Proposed Sale |
9.54 |
62,500 |
596,250 |
0 |
| HEGGIE THERESA | Director |
Mar 20 '26 |
Proposed Sale |
10.11 |
49,933 |
504,620 |
0 |
| HEGGIE THERESA | Director |
Mar 20 '26 |
Option Exercise |
6.30 |
49,933 |
314,578 |
115,285 |
| HEGGIE THERESA | Director |
Mar 20 '26 |
Sale |
10.11 |
49,933 |
504,823 |
65,352 |
| Barnes Alane P | Chief Legal Officer |
Mar 16 '26 |
Option Exercise |
5.51 |
150,000 |
826,500 |
550,703 |
| Barnes Alane P | Chief Legal Officer |
Mar 16 '26 |
Sale |
9.15 |
150,000 |
1,372,500 |
400,703 |
| Barnes Alane P | Officer |
Mar 16 '26 |
Proposed Sale |
9.15 |
150,000 |
1,372,007 |
0 |
3.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):